The Global Health Innovative Technology Fund (GHIT Fund), headquartered in Japan, is an international public-private partnership between the Government of Japan (Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare), seven Japanese pharmaceutical and diagnostics companies (Astellas, Chugai, Eisai, Daiichi Sankyo, Shionogi, Sysmex and Takeda), the Bill & Melinda Gates Foundation, Wellcome Trust, and United Nations Development Programme. GHIT funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world. GHIT is the first public-private partnership fund to involve a national government, a UN agency, a consortium of pharmaceutical and diagnostics companies, and international philanthropic foundations.
The Global Health Innovative Technology Fund (GHIT Fund), headquartered in Japan, is an international public-private partnership between the Government of Japan (Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare), seven Japanese pharmaceutical and diagnostics companies (Astellas, Chugai, Eisai, Daiichi Sankyo, Shionogi, Sysmex and Takeda), the Bill & Melinda Gates Foundation, Wellcome Trust, and United Nations Development Programme. GHIT funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world. GHIT is the first public-private partnership fund to involve a national government, a UN agency, a consortium of pharmaceutical and diagnostics companies, and international philanthropic foundations.
Company Information
- Industry
- Company Type
- Nonprofit
- Founded
- 2013
- Employee Range
- 11-50
- Revenue Range
- Not available
Location
- Address
- Ark Hills Sengokuyama Mori Tower 25F Tokyo
- City
- Region
- Postal Code
- 106-0032
- Country